ArticleActa medica Lituanic2016

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience.

Edita Baltruškevičienė et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.